Following Strong Phase III Results, BMS Plans to Seek Approval for AML Candidate CC-486

Bristol-Myers Squibb is looking to start 2020 on the right foot by filing a New Drug Application for its acute myeloid leukemia treatment CC-486 after data shows the medication extends survival time for AML patients.